ABAhitagni Biswas

Ahitagni Biswas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahitagni Biswas has a total of 223 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-Term Quality of Life Outcomes in Oral Cavity Cancer Survivors: Cross-sectional Evaluation Using the EORTC QLQ-H&N43 in a North Indian Population

    by Karthika Chettuvatti, Kapil Sikka, Anjali V. Ramdulari, Alok Thakar, Smriti Panda, Chirom Amit Singh, Rajeev Kumar, Hitesh Verma, Suman Bhasker, Ahitagni Biswas, et al.

  • Open Access

    Consensus Building for Radiotherapy Quality Assurance: A Multicenter Methodological Narrative From India (Standardised Unified Radiotherapy Quality Assurance)

    by Sanjoy Chatterjee, Rimpa Achari, Moses Arunsingh, Selvamani Backianathan, Tapesh Bhattacharya, Ahitagni Biswas, Santam Chakraborty, Sayan Chakraborty, Sushmita Ghoshal, Sarah Griffin, et al.

    PURPOSE: The incidence of cancer is rising in India, and radiotherapy plays a vital role in the management of most cancers. More radiotherapy centers are being set up across the country to cater to this need. Quality assurance (QA) of radiotherapy is crucial to minimize risks and ensure best outcomes for all patients receiving radiotherapy. We outline an effort to develop a standardized radiotherapy QA program implementable across India through a consensus process among stakeholders. METHODS: The team structured a Standardised Unified Radiotherapy QA model (SURAQSA), a program of pan-India radiotherapy QA incorporating elements of radiotherapy trials QA, adapted for the Indian health care system. Engagement of a cross-section of radiation oncologists working across India to achieve consensus on the issue was essential. This paper describes the consensus development process among the diverse Indian centers/professionals in support of the SURAQSA program. The statement was introduced to clinicians through the vehicle of an abbreviated Delphi consensus process, with guidance from the Royal College of Radiologists (United Kingdom). We outline the elements of the SURAQSA program and describe the consensus adopted. RESULTS: Thirteen centers from across India were represented in the workshop. Three of the consensus statements on external QA of each center, prospective peer review of contours, plan quality measures, and protocol-driven management, as the basic requirements received unanimous support. Consensus was also achieved on the pilot subsite for this exercise with minor disagreement. CONCLUSION: This report showed feasibility of a wide stakeholder engagement to deliver focused outputs and is a huge step toward formulating site-specific radiotherapy QA programs. The process allowed oncologists to highlight the need to take essential steps for radiotherapy safety across centers with varying availability of trained manpower and infrastructure.

  • Open Access

    Impact of Rituximab Maintenance on outcomes in Follicular Lymphoma: An Indian experience

    by Harish Pant, Ajay Gogia, Atul Sharma, Naveet Wig, Hari Krishna Raju Sagiraju, Saumyaranjan Mallick, Ritu Gupta, Ahitagni Biswas

  • Open Access

    Multidisciplinary Tumor Board Evaluation of Pediatric Patients with Adrenocortical Tumors Across Seven International Centers

    by Maria Riedmeier, Wiebke Schlötelburg, Shipra Agarwal, Ahitagni Biswas, Saniye Ekinci, Martin Fassnacht, Maria C. B. Villares Fragoso, E. Nazli Gonc, Melis Gultekin, Mithat Haliloglu, et al.

    Background: The management of rare tumors at reference centers with specialized multidisciplinary tumor boards (MTBs) improves patient survival. No international standardized diagnostic and treatment recommendations for pediatric patients with adrenocortical carcinoma (ACC) exist so far. The aim of this case-based study is to determine how congruent treatment recommendations are in different specialized institutions in different countries. Methods: In this cross-sectional, case-based survey study, five anonymized patient cases, including imaging data of pediatric adrenocortical carcinomas (pACCs), were distributed to seven international specialized centers located in Brazil, Germany, India, Italy, Poland, Turkey, and the USA. The centers were tasked with providing recommendations regarding the treatment sequence and modalities, as well as indicating the level of consensus on these decisions within their MTBs. For each case, the treatment approach recommended by the highest number of centers was recorded to calculate an agreement percentage relative to all treatment recommendations made. The consensus level for each case was determined on a scale of 1 to 10, with higher scores indicating greater agreement among MTB members. Results: A total of five patient cases were discussed across seven MTBs, yielding a total of 34 treatment recommendations. The agreement percentages for the primary therapeutic approach for each case were as follows: primary therapeutic approach: 88.6%; surgical approaches: 51.8%; and systemic chemotherapy recommendations: 53%. Conclusions: This study represents the first case-based analysis of international inter-center agreement on pediatric ACC management. Inter-center agreement regarding treatment allocation and sequencing was low, while the level of consensus within each MTB was high. These findings point to potentially significant and clinically relevant differences in treatment standards across centers, highlighting the need for international collaboration and standardized diagnostic and therapeutic recommendations, especially for rare tumors. Increased case-based exchanges between centers are essential to reduce the substantial discrepancies observed here and to further standardize the management of pediatric patients with ACC.


  • Nuances in the Treatment of Ewing Sarcoma of the Head and Neck in a Low–Middle‐Income Country Setting: A Multi‐Disciplinary Approach

    by Archana Sasi, Shuvadeep Ganguly, Alok Thakar, Kapil Sikka, Sandeep Agarwala, Deepam Pushpam, Akash Kumar, Bivas Biswas, Rachna Meel, Ahitagni Biswas, et al.

    Background: Ewing sarcoma of the head and neck (ES‐HN) is a rare subsite of ES, where therapeutic outcomes need to be explored further. Methods: This retrospective study includes ES‐HN patients registered at our center between 2003 and 2019. Demographic details and treatment outcomes were recorded from the hospital database. Prognostic factors for survival were identified by Cox regression. Results: Eighty‐five patients were included. Metastatic disease was seen in nine patients (10.59%). Local therapy included radiotherapy alone ( n = 38; 44.7%), surgery plus radiotherapy ( n = 15; 17.6%), or surgery alone ( n = 8; 9.4%). The median overall survival (OS) was 37.4 months. On multivariable analysis, osseous primary (HR 0.40; p = 0.009) and male sex (HR 0.43; p = 0.023) were associated with superior OS. Leucocytosis (HR 3.46; p = 0.001) was associated with inferior OS. Conclusions: ES‐HN has favorable biology with metastases being rare at baseline. However, leucocytosis, extra‐osseous disease, and female sex are poor prognostic factors. In resource‐challenged settings, difficulties in administering local therapy may contribute to inferior outcomes.


  • Open Access

    Perception of Social Support and Prevalence of Self-Reported Depressive Symptoms among Patients with Head-and-Neck Squamous Cell Carcinoma Treated at a Tertiary Cancer Centre in North India

    by Bhavna Rani, Aditi Prashant Sinha, Kamlesh Kumari Sharma, Barre Vijay Prasad, Muthuvenkatachalam Srinivasan, Ahitagni Biswas

    Objectives: This study was conducted to determine and correlate the perception of social support and the prevalence of self-reported depressive symptoms among patients with head-and-neck squamous cell carcinoma (HNSCC). Materials and Methods: This cross-sectional study included 100 patients with HNSCC receiving treatment at a tertiary cancer centre in north India. They were enrolled by a convenient sampling technique. Subsequently, data regarding sociodemographic profile, clinical profile, perception of social support and prevalence of self-reported depressive symptoms were collected through face-to-face interviews using a subject datasheet, Multidimensional Scale of Perceived Social Support (MSPSS) and Patient Health Questionnaire-9. Results: Most of the HNSCC patients, 37%, were in the 42–54 years age category. A male gender predilection (85%) was noted. The two most common subsites involved were the oral cavity (61%) followed by the oropharynx (26%). A majority, 60% of the patients had high social support. Among the subscales of the MSPSS, high social support was obtained majorly from the family (98%), followed by significant others (66%) and friends (52%). The prevalence of self-reported moderate-to-severe depressive symptoms was noted in 36% of patients. The perception of social support and the prevalence of self-reported depressive symptoms showed a weak negative correlation (r = −0.262, P = 0.008). Conclusion: Despite receiving high social support, there was a high prevalence of self-reported moderate-to-severe depressive symptoms in patients with HNSCC. Therefore, it is pertinent to monitor the mental health of patients afflicted with HNSCC and provide mental health rehabilitation as per their needs.


  • Ewing sarcoma among children 5 years of age or younger: Is it a different disease?

    by Chitrakshi Nagpal, Shuvadeep Ganguly, Archana Sasi, Vivek Kumar, Bivas Biswas, Deepam Pushpam, Akash Kumar, Sandeep Agarwala, Vishesh Jain, Anjan Dhua, et al.

    Introduction: Children ≤5 years of age with Ewing's sarcoma (ES) possibly have a distinct disease biology, data on which are scarce. We evaluated clinical features, outcomes, and prognostic factors of ES among children with age ≤5 years.Methods: Children with ES registered between 2003 and 2019 were included. Baseline clinical and treatment details were retrieved from medical records. Prognostic factors were identified using multivariable Cox regression. Clinical features and outcomes of children ≤5 years were compared with those greater than 5 years by chi‐square and log‐rank tests. Propensity score‐matched (PSM) analysis was done to evaluate the impact of age on survival in the metastatic and localized subgroups.Results: Out of the 859 patients, 86 (10%) were ≤5 years of age (median age 4 years, 60 males [69.8%]). The most common location was the extremities (37.2%), followed by thorax (27.9%) and head and neck (H&N) (22.1%); baseline metastases were seen in 25 patients (29.8%). The median event‐free‐survival (EFS) and overall survival (OS) were 25.6 and 68.7 months, respectively. Metastatic disease predicted inferior OS (hazard ratio [HR] = 2.54, p = .018) and EFS (HR = 2.47, p = .007], symptom duration ≤3 months predicted an inferior OS (HR = 2.17, p = .048). Compared to age greater than 5 years, younger children had more H&N and less pelvic primaries (p < .001) and lesser baseline metastases (p = .037). PSM analysis did not reveal any significant impact of age on OS in the metastatic (HR = 1.59, p = .29) or localized cohort (HR = 1.77, p = .09).Conclusions: Children with ES ≤5 years of age have a distinct favorable clinical presentation. However, age is not an independent prognostic factor for survival outcomes when adjusted for confounders.


  • Treatment outcomes in patients with Ewing sarcoma of the spine in a resource-challenged setting: 17-year experience from a single center in India

    by Archana Sasi, Sindhura Chitikela, Shuvadeep Ganguly, Bivas Biswas, Deepam Pushpam, Akash Kumar, Shah Alam Khan, Venkatesan Sampath Kumar, Shashank Sharad Kale, Ahitagni Biswas, et al.

    Ewing sarcoma (ES) of the spine is a rare childhood cancer with sparse literature on treatment outcomes. We aimed to describe survival outcomes and prognostic factors in patients with spinal ES treated at a single institute in a resource-challenged setting. We conducted a retrospective analysis of patients with spinal ES registered at a tertiary care oncology center between 2003-2019. Clinical patient data was retrieved from hospital records. Cox regression analysis was used to identify the association of baseline clinical parameters with event free survival (EFS) and overall survival (OS). A cohort of 85 patients was analyzed including 38 (45%) patients with metastatic disease. The median age was 15 years with 73% being male. Local therapy was administered in 62 (72.9%) patients with surgery alone in 8 (9.4%), radiotherapy alone in 36 (42.4%) and both in 18 (21.2%) patients. A higher proportion of males received local therapy than females (80.3% versus 59.1%; p = 0.049). The median EFS and OS were 20.1 and 28.6 months, respectively. On univariable analysis, age ≤ 15 years, female sex, serum albumin ≤3.5 g/dL and hemoglobin ≤11 g/dL were associated with inferior EFS while younger age, female sex, hypoalbuminemia and metastatic disease were associated with inferior OS. On multivariable analysis, only hypoalbuminemia was predictive for inferior EFS (HR:2.41; p = 0.005) while hypoalbuminemia (HR:2.06;p = 0.033) and female sex (HR:1.83; p = 0.046) were associated with inferior OS. We concluded that hypoalbuminemia confers poor prognosis in ES spine. Survival outcomes are poorer in females treated in our setting, possibly due to prevailing sex-based biases.


  • Open Access

    A Phase III open-label randomized study to compare the efficacy of lenalidomide–rituximab with bendamustine– rituximab in treatment-naïve follicular lymphoma

    by Sushant Kumar Paikaray, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahit Agni Biswas, Sreeniwas Vishnubhatla, Soumya Mallick

    Introduction: Bendamustine–rituximab (BR) is the preferred regimen for the treatment of naïve follicular lymphoma (FL). Recently, lenalidomide–rituximab (LR), a chemotherapy-free protocol, has shown a good response rate in advanced FL. These regimens have never been compared in a randomized controlled trial for treatment-naïve FL in Indian patients. Materials and Methods: This Phase III open-label randomized controlled trial was conducted to compare the efficacy and safety of BR and LR. Treatment-naïve patients older than 18 years of age, ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤2, who were diagnosed with FL (Stages II–IV) were included in this study. Patients were randomized in a 1:1 ratio to receive six cycles of BR (bendamustine 90 mg/m2 Days 1–2 and rituximab 375 mg/m2 Day 1) every 4 weeks or LR (lenalidomide 20 mg Days 1–21 and rituximab 375 mg/m2) every 4 weeks. The primary end point was complete response (CR) and secondary end points were overall response rate (ORR) and toxicity. Result: We enrolled 40 patients, 20 in each group with a median age of 53 years. The CR rate was 60% and 20% in BR and LR arms, respectively (P = 0.01); however, the ORR was 88.8% and 87.3% in BR and LR arms, respectively (P = 1.0). Anemia (35% versus 10%), skin rash (35% versus 30%), diarrhea (30% versus 10%), vomiting (20% versus 10%), nephrotoxicity (15% versus 0%), and transaminitis (10% versus 0%) were more in LR than in BR, and thrombocytopenia was higher in the BR than in the LR group but statistically not different. All grade toxicities were seen in 90% and 45% in LR and BR, respectively (P = 0.05), but there was no significant difference in Grade 3 or 4 toxicity between the BR and the LR regimens (20% versus 25%). Conclusion: The ORR was similar in both the arms; however, the CR rate was significantly higher in the BR arm. BR was better tolerated than LR. (CTRI/2016/05/006904).


  • Extramedullary Relapse of B Cell Acute Lymphoblastic Leukemia in Bilateral Breasts Treated with Whole Breast Radiotherapy

    by Vivek Ghosh, Swarnaditya Roy, Ekta Dhamija, Ruchi Rathore, Lalit Kumar, Ahitagni Biswas

    Isolated extramedullary relapse of acute lymphoblastic leukemia (ALL) in the breast is extremely rare. We herein report a case of a 38-year-old female with B cell ALL, who had isolated extramedullary relapse initially in the left breast and subsequently in the right breast, 3 and 4 years, respectively, after hematopoietic allogenic stem cell transplantation. She was successfully salvaged with bilateral whole breast radiotherapy, 24 Gy/12 fractions/2.5 weeks. This brief report highlights the importance of awareness of extramedullary leukemic relapse in the breast as one of the differential diagnoses of breast masses in the context of ALL. Since these tumors are extremely radioresponsive, radiation therapy is a safe and effective treatment option for isolated extramedullary relapse of ALL in the breast.